
An investigational vaccine for herpes zoster provided significant benefit to patients 50 and older, with little difference in efficacy among those in their 50s, 60s, and 70s, according to a phase 3 international trial [Zoster Efficacy Study in Adults 50 Years of Age or Older (ZOE-50)].